Tags

Type your tag names separated by a space and hit enter

Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke.
Eur Heart J 2008; 29(22):2800-7EH

Abstract

AIMS

To investigate the effect of oral isoflavone supplement on vascular endothelial function in patients with established cardiovascular disease.

METHODS AND RESULTS

A randomized, double-blinded, placebo-controlled trial was performed to determine the effects of isoflavone supplement (80 mg/day, n = 50) vs. placebo (n = 52) for 12 weeks on brachial flow-mediated dilatation (FMD) in patients with prior ischaemic stroke. Compared with controls, FMD at 12 weeks was significantly greater in isoflavone-treated patients [treatment effect 1.0%, 95% confidence interval (95% CI) 0.1-2.0, P = 0.035]. Adjusted for baseline differences in FMD, isoflavone treatment was independently associated with significantly less impairment of FMD at 12 weeks (odds ratio 0.32, 95% CI 0.13-0.80, P = 0.014). The absolute treatment effect of isoflavone on brachial FMD was inversely related to baseline FMD (r = -0.51, P < 0.001), suggesting that vasoprotective effect of isoflavone was more pronounced in patients with more severe endothelial dysfunction. Moreover, isoflavone treatment for 12 weeks resulted in a significant decrease in serum high-sensitivity (hs)-C-reactive protein level (treatment effect -1.7 mg/L, 95% CI -3.3 to -0.1, P = 0.033). Nevertheless, isoflavone did not have any significant treatment effects on nitroglycerin-mediated dilatation, blood pressure, heart rate, serum levels of fasting glucose and insulin, haemoglobin A1c, and oxidative stress as determined by serum superoxide dismutase, 8-isoprostane, and malondialdehyde (all P > 0.05).

CONCLUSION

This study demonstrated that 12 week isoflavone treatment reduced serum hs-C-reactive protein and improved brachial FMD in patients with clinically manifest atherosclerosis, thus reversing their endothelial dysfunction status. These findings may have important implication for the use of isoflavone for secondary prevention in patients with cardiovascular disease, on top of conventional interventions.

Authors+Show Affiliations

Cardiology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, PR China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18812325

Citation

Chan, Yap-Hang, et al. "Reduction of C-reactive Protein With Isoflavone Supplement Reverses Endothelial Dysfunction in Patients With Ischaemic Stroke." European Heart Journal, vol. 29, no. 22, 2008, pp. 2800-7.
Chan YH, Lau KK, Yiu KH, et al. Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke. Eur Heart J. 2008;29(22):2800-7.
Chan, Y. H., Lau, K. K., Yiu, K. H., Li, S. W., Chan, H. T., Fong, D. Y., ... Tse, H. F. (2008). Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke. European Heart Journal, 29(22), pp. 2800-7. doi:10.1093/eurheartj/ehn409.
Chan YH, et al. Reduction of C-reactive Protein With Isoflavone Supplement Reverses Endothelial Dysfunction in Patients With Ischaemic Stroke. Eur Heart J. 2008;29(22):2800-7. PubMed PMID: 18812325.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke. AU - Chan,Yap-Hang, AU - Lau,Kui-Kai, AU - Yiu,Kai-Hang, AU - Li,Sheung-Wai, AU - Chan,Hiu-Ting, AU - Fong,Daniel Yee-Tak, AU - Tam,Sidney, AU - Lau,Chu-Pak, AU - Tse,Hung-Fat, Y1 - 2008/09/23/ PY - 2008/9/25/pubmed PY - 2009/1/1/medline PY - 2008/9/25/entrez SP - 2800 EP - 7 JF - European heart journal JO - Eur. Heart J. VL - 29 IS - 22 N2 - AIMS: To investigate the effect of oral isoflavone supplement on vascular endothelial function in patients with established cardiovascular disease. METHODS AND RESULTS: A randomized, double-blinded, placebo-controlled trial was performed to determine the effects of isoflavone supplement (80 mg/day, n = 50) vs. placebo (n = 52) for 12 weeks on brachial flow-mediated dilatation (FMD) in patients with prior ischaemic stroke. Compared with controls, FMD at 12 weeks was significantly greater in isoflavone-treated patients [treatment effect 1.0%, 95% confidence interval (95% CI) 0.1-2.0, P = 0.035]. Adjusted for baseline differences in FMD, isoflavone treatment was independently associated with significantly less impairment of FMD at 12 weeks (odds ratio 0.32, 95% CI 0.13-0.80, P = 0.014). The absolute treatment effect of isoflavone on brachial FMD was inversely related to baseline FMD (r = -0.51, P < 0.001), suggesting that vasoprotective effect of isoflavone was more pronounced in patients with more severe endothelial dysfunction. Moreover, isoflavone treatment for 12 weeks resulted in a significant decrease in serum high-sensitivity (hs)-C-reactive protein level (treatment effect -1.7 mg/L, 95% CI -3.3 to -0.1, P = 0.033). Nevertheless, isoflavone did not have any significant treatment effects on nitroglycerin-mediated dilatation, blood pressure, heart rate, serum levels of fasting glucose and insulin, haemoglobin A1c, and oxidative stress as determined by serum superoxide dismutase, 8-isoprostane, and malondialdehyde (all P > 0.05). CONCLUSION: This study demonstrated that 12 week isoflavone treatment reduced serum hs-C-reactive protein and improved brachial FMD in patients with clinically manifest atherosclerosis, thus reversing their endothelial dysfunction status. These findings may have important implication for the use of isoflavone for secondary prevention in patients with cardiovascular disease, on top of conventional interventions. SN - 1522-9645 UR - https://www.unboundmedicine.com/medline/citation/18812325/Reduction_of_C_reactive_protein_with_isoflavone_supplement_reverses_endothelial_dysfunction_in_patients_with_ischaemic_stroke_ L2 - https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehn409 DB - PRIME DP - Unbound Medicine ER -